Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individuals

1 Sept 2005

Abstract excerpt

OBJECTIVES: The site of action of efavirenz is inside HIV-infected cells. Measurement of intracellular (IC) concentrations of efavirenz may therefore provide further understanding of therapeutic failure, especially where virological rebound occurs despite adequate plasma levels, and a lack of detectable viral resistance. Here, we determined IC and plasma pharmacokinetics of efavirenz and their relationship with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV/AIDS drug development and treatment
Share to HIV-related health complications and treatments
Share to Pneumocystis jirovecii pneumonia detection and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16141277
DOI: 10.1093/jac/dki308

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Intracellular and plasma pharmacokinetics of efavirenz in HIV-infected individualsPMID 16141277Read ↗

Intracellular and plasma pharmacokinetics of nevirapine in human immunodeficiency virus-infected individualsSemantic proximity Read ↗

Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients.Semantic proximity Read ↗

Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients.Semantic proximity Read ↗

Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study.Semantic proximity Read ↗

Orosomucoid (alpha1-acid glycoprotein) plasma concentration and genetic variants: effects on human immunodeficiency virus protease inhibitor clearance and cellular accumulation.Semantic proximity Read ↗

Plasma and Intracellular Population Pharmacokinetic Analysis of Tenofovir in HIV-1-Infected PatientsSemantic proximity Read ↗

Efavirenz: What is known about the cellular mechanisms responsible for its adverse effectsSemantic proximity Read ↗

Pharmacogenetics of Efavirenz Exposure in Cervicovaginal Fluid during Pregnancy and Postpartum.Semantic proximity Read ↗

Induction of Multiple Drug Transporters by EfavirenzSemantic proximity Read ↗

Long-term effect of efavirenz autoinduction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients.Semantic proximity Read ↗

Effect of transporter modulation on the emergence of nelfinavir resistance in vitro.Semantic proximity Read ↗

Population Approach to Efavirenz Therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.